JP2025502095A5 - - Google Patents
Info
- Publication number
- JP2025502095A5 JP2025502095A5 JP2024541033A JP2024541033A JP2025502095A5 JP 2025502095 A5 JP2025502095 A5 JP 2025502095A5 JP 2024541033 A JP2024541033 A JP 2024541033A JP 2024541033 A JP2024541033 A JP 2024541033A JP 2025502095 A5 JP2025502095 A5 JP 2025502095A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298133P | 2022-01-10 | 2022-01-10 | |
| US63/298,133 | 2022-01-10 | ||
| US202263307911P | 2022-02-08 | 2022-02-08 | |
| US63/307,911 | 2022-02-08 | ||
| US202263327986P | 2022-04-06 | 2022-04-06 | |
| US63/327,986 | 2022-04-06 | ||
| PCT/US2023/060358 WO2023133577A1 (en) | 2022-01-10 | 2023-01-10 | Methods of treating or reducing risk of transplant rejection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025502095A JP2025502095A (ja) | 2025-01-24 |
| JPWO2023133577A5 JPWO2023133577A5 (https=) | 2026-01-20 |
| JP2025502095A5 true JP2025502095A5 (https=) | 2026-01-20 |
Family
ID=87074361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541033A Pending JP2025502095A (ja) | 2022-01-10 | 2023-01-10 | 移植拒絶反応のリスクを処置または低減する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230287132A1 (https=) |
| EP (1) | EP4463182A1 (https=) |
| JP (1) | JP2025502095A (https=) |
| KR (1) | KR20240131437A (https=) |
| AU (1) | AU2023205152A1 (https=) |
| CA (1) | CA3242941A1 (https=) |
| MX (1) | MX2024008562A (https=) |
| WO (1) | WO2023133577A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040932A1 (en) | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2970493T (pt) * | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| WO2017040932A1 (en) * | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
-
2023
- 2023-01-10 AU AU2023205152A patent/AU2023205152A1/en active Pending
- 2023-01-10 WO PCT/US2023/060358 patent/WO2023133577A1/en not_active Ceased
- 2023-01-10 KR KR1020247026684A patent/KR20240131437A/ko active Pending
- 2023-01-10 US US18/152,519 patent/US20230287132A1/en active Pending
- 2023-01-10 CA CA3242941A patent/CA3242941A1/en active Pending
- 2023-01-10 JP JP2024541033A patent/JP2025502095A/ja active Pending
- 2023-01-10 EP EP23737837.7A patent/EP4463182A1/en active Pending
-
2024
- 2024-07-08 MX MX2024008562A patent/MX2024008562A/es unknown